GoodRx (GDRX)
(Real Time Quote from BATS)
$9.02 USD
+0.11 (1.24%)
Updated Jul 24, 2024 12:16 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
GDRX 9.02 +0.11(1.24%)
Will GDRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GDRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GDRX
ICLR vs. GDRX: Which Stock Is the Better Value Option?
GoodRx (GDRX) Reports Q1 Earnings: What Key Metrics Have to Say
GDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
GoodRx Holdings, Inc. (GDRX) Misses Q1 Earnings Estimates
Premier, Inc. (PINC) Q3 Earnings and Revenues Surpass Estimates
Countdown to GoodRx (GDRX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Other News for GDRX
GoodRx Holdings Underperform Rating: Concerns Over Biosimilar Affordability and Generic Reimbursement Market Dynamics
Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira®
GoodRx offers exclusive discount to biosimilar targeting AbbVie’s Humira
Boehringer Ingelheim, GoodRx enter exclusive patient affordability initiative
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), GoodRx Holdings (GDRX) and Organon (OGN)